With the number of antibiotic resistant bacterial infections on the rise, novel ways to discover new antimicrobials are increasingly important. A team of researchers has developed a new web tool that speeds the discovery of drugs to kill Gram-negative bacteria. The program, named eNTRyway, predicts compound accumulation from its structure and offers insights into discrete chemical changes that can convert drugs that kill other bacteria into drugs to fight Gram-negative infections.
In this GEN webinar, sponsored by Carterra, we will demonstrate how modern day high-throughput surface plasmon resonance (HT-SPR™) has facilitated a paradigm shift in antibody screening, enabling higher information content assays to be conducted earlier in the research pipeline to streamline lead selection. This essentially combines screening and detailed characterization in the same step, condensing months of work into days.
Researchers at the Scripps Institute have invented an efficient method for making a synthetic version of bilobalide—a natural product of the Ginkgo tree. The ability to synthesize the metabolite provides a platform to investigate its property as an insecticide or as a potential pharmaceutical.
Combining synthetic chemistry, genetics, enzymology, computational chemistry, and structural biology, researchers have uncovered a surprising chemical twist in how some fungal-derived compounds are made in nature. This work may be useful in designing and creating new compounds in the future.
In this GEN webinar, we will discuss how the VIPS™ (Verified in-situ Plate Seeding) system, in combination with the SAL Scientific single-cell cloning supplements, offer customers a high-efficiency solution which ensures plates are populated with high numbers of healthy single cells that grow into resultant colonies for screening, expansion and further selection to master cell banks.
In this GEN webinar, we will review pressure-assisted protein refolding and pressure perturbation coupled with MMS to study protein stability in biopharmaceutical formulations.
Scientists have started to uncover why a Zika virus infection causes microcephaly in some babies but not in others. Linking the risk of microcephaly to certain features of maternal antibodies, the research has implications for Zika virus vaccine development.
Researchers at University of Utah Health have shown that Clostridia bacteria in the microbiome prevent mice from becoming obese by blocking fat absorption, but only as long as they have a normal functioning immune system. In animals genetically engineered to have a lack of gut IgA, Clostridia are depleted and Desulfovibrio bacteria instead flourish and promote lipid uptake and obesity.
A simple drug screening platform based on a zebrafish (Danio rerio) larval spinal cord transection model shows promise to accelerate the discovery of novel therapeutics for spinal cord injury. The system can test a large number of molecules for their ability to accelerate the regeneration of the zebrafish spinal cord.
A team led by researchers at Sangamo Therapeutics has shown the first, direct, demonstration of allele-selective transcriptional repression at the huntingtin locus. This opens up a novel therapeutic approach to targeting the gene responsible for Huntington's disease.